Synergistic anticancer effects of everolimus (RAD001) and Rhein on gastric cancer cells via phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway

Feng Gao¹, Rui Li², Pei-Feng Wei³, Li Ou⁴, Min Li⁵, Yang Bai⁶, Wen-Jia Luo⁷, and Zhen Fan⁸

¹Teaching and Research Office of Chinese Pharmacy, The College of Pharmacy of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China; ²Department of Emergency, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China; ³The Office of Drug Clinical Trial Institution, The Second Affiliated Hospital of Shaanxi University of traditional Chinese Medicine, Xianyang, Shaanxi, China; ⁴Department of Gastroenterology, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang712000, Shaanxi, China

ABSTRACT
Everolimus (RAD001) is a mTOR inhibitor and is widely used for the treatment of gastric cancer (GC). Evidence suggests that Rhein has anticancer effect on GC. But the synergistic effect and mechanism of RAD001 and Rhein combination on GC is not clear. The current study aims to clarify the combination of RAD001 and Rhein in GC treatment. We found Rhein dose-dependently repressed MGC-803 cell viability (50% inhibition concentration (IC50) value = 94.26 μM). Rhein (80 μM) significantly suppressed GC cell proliferation and invasion. RAD001 dose-dependently repressed MGC-803 cells viability (IC50 value = 45.41 nM). The combination of Rhein and RAD001 repressed MGC-803 cells viability, invasion, and proliferation compared to the administration of Rhein or RAD001 alone. Protein levels of epithelial-mesenchymal transition (EMT)-related molecules E-cadherin, N-cadherin and Vimentin expressions were significantly affected by the combination of Rhein and RAD001. The combination of Rhein and RAD001 significantly facilitated cell apoptosis and up-regulated expressions of cell apoptosis and cycle-related protein p53, cyclin-dependent kinase 4 (CDK4) and cyclin D1 compared to the administration of Rhein or RAD001 alone. Moreover, the combination of Rhein and RAD001 repressed the expressions of phosphorylation-phosphoinositide-3-kinase (p-PI3K), p-protein kinase B (p-AKT) and p-mammalian target of rapamycin (p-mTOR). Finally, the combination of RAD001 and Rhein significantly decreased tumor weight and volume, suppressed the expressions of p-PI3K, p-Akt and p-mTOR, and repressed cell proliferation marker Ki-67 expression, which exerted synergistic cancer prevention in GC in vivo. Overall, the combination of Rhein and RAD001 exert synergistic cancer prevention in GC via PI3K/Akt/mTOR pathway.

Introduction
Gastric cancer (GC) is a multifactorial-associated disease in the digestive system in the United States, which has an increasing number in new cases due to risk factors, including H. pylori infection, high salt intake, and smoking [1]. Most GC patients are diagnosed in advanced stage, which already show distant metastasis, such as that to the lung, bone and liver [2]. The progression of GC is complex which is related with the tumor cell proliferation, invasion, and migration [3]. Although some treatments have gained improvements in suppressing GC cell proliferation, invasion and migration [4,5], the five-year survival rate is not high [6]. Therefore, more effective treatments are needed for improving the survival rate of GC patients.

RAD001 (Everolimus), a mTOR inhibitor, is widely used for treating clear-cell renal cell carcinoma, breast cancer, and unresectable fibrolamellar carcinoma [7–9]. The PI3K/Akt/mTOR pathway plays an important role in modulating the biological functions of cancer cells, and PI3K/Akt/mTOR pathway activation is tightly related with GC progression [10,11]. Therefore, RAD001 is now commonly used to treat GC in clinic [12,13]. However, the dysregulation PI3K/Akt/mTOR pathway is related with chemoresistance resistance in patients with GC, and RAD001 resistance in GC will not effectively increase overall survival of GC patients [14,15].

Rhein is an anthraquinone component extracted from many medicinal herbs in traditional Chinese medicine, including polygonum multiflorum and...
rhubarb (Rheum rhabarbarum), which can exert anticancer functions via suppressing cancer cells proliferation and migration [16,17]. Recently, the combination of RAD001 and other drugs, such as capcitabine, mitogen-activated protein kinase kinase (MEK) inhibitor, and platinum, can increase overall survival of GC patients [18,19]. However, studies focused on the combination of RAD001 and Rhein in GC treatment are still lacked.

The current study assumes that RAD001 and Rhein combination has better inhibition effects on the activity of GC cells. We aim to investigate synergistic cancer prevention of RAD001 and Rhein in GC cell proliferation, growth and invasion, which may supply a rationale for RAD001 and Rhein combination in GC treatment.

Materials and methods

Cell culture and treatment

Human GC cells (MGC-803) were kept in our laboratory and were maintained in RPMI 1640 Medium (Gibco, CA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco) at 37°C in 5% CO2 incubator [20]. Rhein was purchased from Sigma-Aldrich (MO, USA) with a purity ≥ 95%, and RAD001 (Everolimus) was purchased from Sigma-Aldrich. The drugs (Rhein and RAD001) were dissolved in saline.

Measurement of IC50 values by MTT assay

MGC-803 cells were cultured in 96-well plates at a density of 2 × 10^3 cells/well for 12 h. After the treatment of different concentrations of Rhein (0, 10, 20, 40, 80, 160 μM) and RAD001 (0, 2.5, 5, 10, 20, 40, 80, 160 nM) for 48 h, 10 μL/well MTT solution (Beyotime Biotechnology, Nantong, China) was added and cultured for 4 h. Formazan solution (100 μL/well) was added to MGC-803 cells and cultured for 4 h at 37°C. The absorbance was measured by a microplate reader (BioTek, Vermont, USA) at 570 nm. The IC50 values of RAD001 or Rhein against MGC-803 cells were calculated [21].

Transwell assay

Transwell chamber (8 μm pore size, 24-well; Corning, NY, USA) was used to determine the invasion of MGC-803 cells [22]. After the treatment of Rhein and RAD001 for 48 h, MGC-803 cells (5 × 10^4) were seeded in serum-free RPMI 1640 medium (Gibco) in the upper chamber precoated with matrigel (Corning). The lower chamber was added with RPMI 1640 medium supplemented with 10% FBS (Gibco). After cultured for 24 h, invaded MGC-803 cells in the lower chamber were collected and stained with 5% crystal violet solution. Images were obtained by a microscope (Nikon, Japan). Three images of ten random fields of each chamber were obtained, and number of invasive cells was counted.

EdU staining

MGC-803 cell proliferation at different groups was determined using EdU staining [23]. MGC-803 cells at a density of 5 × 10^3 cells/well were seeded in 96-well plates and incubated with 10 μM EdU (RiboBio, Guangzhou, China) for 120 min. MGC-803 cells were fixed with 4% parafomaldehyde for 15 min at 25°C. After stained with DAPI, images were acquired using a fluorescence microscope (Olympus, Japan).

Flow cytometry

MGC-803 cells at different groups were collected in 1× Annexin V-FITC binding buffer (195 μL; Beyotime Biotechnology) to a density of 1 × 10^6 cells/mL [24]. Then, Annexin V-FITC reagent (10 μL) was added to each tube that contained 1 × 10^6 cells. Propidium iodide (PI; 10 μL) was added to MGC-803 cells. Cell apoptosis was distinguished by a flow cytometry (BD Biosciences, NJ, USA).

TUNEL assay

MGC-803 cell apoptosis was detected by TUNEL assay kit (Beyotime Biotechnology). MGC-803 cells (2 × 10^6 cells/mL) was collected and washed with 4% paraformaldehyde for 30 min at 25°C. Later, MGC-803 cells were added with 50 μL
TUNEL solution at 37°C in the darkness for 60 min. MGC-803 cells can be analyzed by a fluorescence microscope.

**Western blotting**

Protein was extracted from MGC-803 cells at different groups and tumor tissues using RIPA buffer containing PMSF. Proteins (50 μg) were resolved on 10% SDS-PAGE and electrotransferred on polyvinylidene fluoride membranes (Invitrogen, CA, USA). The primary antibodies used here were anti-PI3K, anti-p-PI3K, anti-AKT, anti-p-AKT, anti-mTOR, anti-p-mTOR, anti-E-cadherin, anti-N-cadherin, anti-Vimentin, anti-p53, anti-CDK4, anti-CyclinD1 or anti-beta-actin from Cell Signaling Technology or Abcam. Then, the membranes were incubated with secondary antibody and target proteins were analyzed by ImageLab software (Bio-Rad, CA, USA) [25].

**KEGG pathway enrichment analysis**

The TCMIO database (http://tcmiol.xielab.net/) is a commonly used database for providing information for Traditional Chinese Medicine [26]. We can generate herb-ingredient-target networks online, and KEGG pathway enrichment analysis for target polygonum multiflorum is available. P < 0.05 indicated statistically significant.

**Xenograft model**

Female CB-17 SCID mice (specific-pathogen-free, five-week-old) were purchased from Beijing Charles River Co. and maintained in sterile condition. MGC-803 cells (1 × 10⁵) were inoculated subcutaneously into each CB-17 SCID mouse. Mice were divided into control, RAD001, Rhein, RAD001+ Rhein groups, with six mice in each group. Mice received Rhein (60 mg/kg) or/and RAD001 (5 mg/kg) by oral administration. Tumor volumes were measured every five days as follows: volume = length×width²/2. All mice were sacrificed 28 days later, and tumor xenografts were excised and weighed. All studies were supported by Animal Care and Research Committee of The college of Pharmacy of Shaanxi University of Chinese Medicine.

**Immunohistochemical (IHC) staining**

Tumor tissues were fixed and paraffin embedded, and 4 μm-thick sections were collected from paraffin specimens [27]. The sections were heated in citrate buffer and immunostained with anti-Ki-67. Ki-67 expression was evaluated under a microscope (Olympus, Japan).

**Statistical analysis**

Data were expressed as mean ± SD. Differences between groups were performed by Student’s t test. Differences among multiple groups were performed by One-way analysis of variance (ANOVA) for multiple comparisons followed by Bonferroni post hoc test. Synergistic and comparative RAD001/Rhein analyses on GC cell experiment were statistically calculated with R value. P value <0.05 was identified as significant.

**Results**

We aim to investigate synergistic cancer prevention and the underlying mechanism of RAD001 and Rhein in MGC-803 cells proliferation and invasion in vitro and in vivo. We calculated IC50 value for Rhein and RAD001 dose response, and finish-dose selection for Rhein and RAD001. We found Rhein and RAD001 combination repressed MGC-803 cells proliferation and invasion in vitro through PI3K/Akt/mTOR pathway and verified our hypothesis in vivo.

**Rhein suppressed the proliferation and invasion of MGC-803 cells**

The structure of Rhein is shown in Figure 1(a). A dose-dependent inhibition of MGC-803 cell survival was observed by different concentrations of Rhein treatment, and IC50 value for Rhein was 94.26 μM (Figure 1(b)). So, 80 μM of Rhein without causing significant toxicity was chosen for further experiments. We observed that MGC-803 cell survival was significantly repressed at a concentration of 80 μM Rhein (Figure 1(b)). Rhein (80 μM) significantly repressed the number of invasive MGC-803 cells compared to Rhein (0 μM) group (Figure 1(c)). EdU assay showed
that EdU-positive cells was significantly inhibited in Rhein (80 μM) group compared to Rhein (0 μM) group (Figure 1(d)). So, the effective response of Rhein (80 μM) can reduce the activity of MGC-803 cells.

**Synergistic inhibition impacts of Rhein and RAD001 on MGC-803 cell proliferation and invasion**

RAD001 structure is shown in Figure 2(a). It showed a dose-dependent inhibition of cell survival in MGC-803 cells, and IC50 value for RAD001 was 45.41 nM (Figure 2(b)). So, a concentration of 40 nM without causing significant toxicity was chosen to treat MGC-803 cells for further experiments. We further observed the effect of Rhein (80 μM) and RAD001 (40 nM) combination on MGC-803 cell survival. MGC-803 cell survival was significantly inhibited by treatment of Rhein and RAD001 (Figure 2(c)), MGC-803 invasive cells were significantly repressed in Rhein and RAD001 combination group compared to the other three groups (Figure 2(d)), and EdU assay showed EdU-positive cells was significantly decreased in Rhein and RAD001 combination group compared to the other three groups (Figure 2(e)). As shown in Figure 2(f), light microscope images of MGC-803 cells in control, the combination of Rhein and RAD001 group, and the administration of Rhein or RAD001 alone groups were observed. Moreover, protein levels of EMT-related molecule E-cadherin was significantly up-regulated in Rhein (80 μM) and RAD001 (40 nM) group compared to the other three groups, whereas N-cadherin and Vimentin
expressions were significantly down-regulated in Rhein (80 μM) and RAD001 (40 nM) group compared to the other three groups (Figure 2(g)).

**Synergistic promotion impacts of Rhein and RAD001 on MGC-803 cell apoptosis**

Rhein and RAD001 together significantly promoted MGC-803 cell apoptosis compared to the other three groups (Figure 3(a)). TUNEL assay further showed that the treatment of Rhein and RAD001 together significantly promoted MGC-803 cell apoptosis compared to the other three groups (Figure 3(b)). Moreover, compared to the other three groups, the treatment of Rhein and RAD001 together significantly up-regulated the protein expressions of p53, CDK4 and Cyclin D1 (Figure 3(c)).

**Synergistic inhibition effects of Rhein and RAD001 on PI3K/AKT/mTOR pathway**

A KEGG pathway enrichment analysis associated with target Polygonum multiflorum was performed using TCMI O database, and the results are shown in Figure 4(a). According to the KEGG pathways in Figure 4(a), Polygonum-multiflorum-targeted pathways are enriched in the following, e.g., PI3K-Akt signaling pathway, T cell receptor signaling pathway, sphingolipid signaling pathway, TNF signaling pathway, MAPK signaling pathway. The target polygonum multiflorum was mainly enriched in PI3K-Akt signaling pathway, which gained the highest score (Figure 4(a)). The scores of other signaling pathways were much lower than the score of PI3K-Akt signaling pathway, so we chose PI3K-Akt signaling pathway for this study. In addition, compared to
the other three groups, the treatment of Rhein and RAD001 together significantly down-regulated protein levels of phosphorylation of PI3K (p-PI3K), p-AKT, and p-mTOR (Figure 4(b)). These results indicated that the synergistic inhibition effects of Rhein and RAD001 on the activation of PI3K/AKT/mTOR pathway.

**Synergistic inhibition impacts of Rhein and RAD001 on MGC-803 cell proliferation in vivo**

To verify whether Rhein and RAD001 could synergistically repress MGC-803 cell proliferation in vivo, Rhein (60 mg/kg) and RAD001 (5 mg/kg) were used for the observation of the anticancer effects on MGC-803 cell xenograft mouse model. The combination of Rhein and RAD001 significantly repressed tumor weight, and decreased tumor volume at day 18 to day 28 than control group, indicating they delayed xenograft growth (Figure 5(a-c)). In addition, compared with the other three groups, the combination of Rhein and RAD001 significantly down-regulated p-PI3K, p-AKT and p-mTOR protein expressions (Figure 5(d)), indicating Rhein and RAD001 combination inhibited PI3K/AKT/mTOR pathway activation in vivo. Furthermore, combination of Rhein and RAD001 significantly decreased tumor cell proliferation marker Ki-67 expression by IHC staining (Figure 5(e)).

**Discussion**

Rhein, an anthraquinone component extracted from herbs in traditional Chinese medicine such as polygonum multiflorum and rhubarb, has been used for over 1000 years in China for alleviating inflammation due to its strong curative effects and few side effects [28]. Recent studies have implicated Rhein exerts anticancer effects on a variety of cancers through suppressing cancer cell growth and invasion, and promoting cancer cell apoptosis [17,29,30]. Li et al. have found that Rhein induces human GC cell SGC-7901 apoptosis in a dose-dependent manner [31]. However, the effects of Rhein on GC cell growth, proliferation, and invasion are not clarified. We found that Rhein repressed GC cell viability in a dose-dependent manner, and inhibited GC cell invasion. With about 47% cell viability reduction, a significant anticancer impact was attained when the concentration of Rhein at 80 μM.

Combination treatment is considered as a promising therapeutic method in GC [32].

---

**Figure 3.** Synergistic promotion impacts of Rhein and RAD001 on MGC-803 cell apoptosis. Rhein (80 μM) and RAD001 (40 nM) were used to treat MGC-803 cells. A. Rhein and RAD001 combination in MGC-803 cell apoptosis was detected using flow cytometry. B. Rhein and RAD001 combination in MGC-803 cell apoptosis was detected by TUNEL assay. C. The effect of Rhein and RAD001 combination on p53, CDK4 and Cyclin D1 expressions was measured using Western blotting. *p < 0.05.
Several studies have provided evidences that the combination of RAD001 and other drugs (Asp-Glu-Ala-Asp box helicase 5, celecoxib, cyclophosphamide) can improve GC cell sensitivity to RAD001, which exert better anticancer effects on GC [12,14,33]. In previous researches, Rhein can sensitize human pancreatic cancer cells and human colorectal cancer cells to erlotinib [34,35]. The combination of Rhein and doxorubicin can promote the treatment impact of doxorubicin in ovarian cancer cells and reduce drug resistance of ovarian cancer cells [36]. Rhein and atezolizumab combination has stronger therapeutic effects on mouse breast cancer via repressing the growth and promoting the apoptosis than atezolizumab therapy group [37]. These researches provide evidences that Rhein can sensitize a variety of cancer cells to anticancer drugs. However, whether Rhein can enhance anticancer effects of RAD001 on GC is still not clear. We assumed that Rhein might enhance the antitumor effect of RAD001 on GC through suppressing GC cell proliferation and invasion, and induce apoptosis, which had better inhibitory effects on GC than RAD001 alone. Finally, we found that Rhein and RAD001 combination has stronger anticancer effects on GC cells through inhibiting the cancer cell invasion and proliferation than the administration of Rhein or RAD001 alone, which will enrich the literature.

According to previous reports, RAD001 can induce cell cycle arrest at G0/G1 phase and promote GC cell apoptosis [12,38]. In addition, Rhein has antiapoptotic effects on GC cells [31], can induce cell cycle arrest at the G0/G1 phase, S phase or G2 phase in human colorectal cancer cells and liver cancer cells, as well as reduce cell

---

**Figure 4.** Synergistic inhibition impacts of Rhein and RAD001 on PI3K/AKT/mTOR pathway. A. KEGG pathway enrichment analysis associated with the target polygonum multiflorum. B. The effect of Rhein and RAD001 combination on PI3K/AKT/mTOR pathway proteins expressions was measured using Western blotting. *p < 0.05.
cycle-related protein levels [35,39,40]. However, the effect of Rhein and RAD001 combination on GC cell apoptosis is not clear. We showed that Rhein and RAD001 combination remarkably facilitated GC cell apoptosis than the administration of Rhein or RAD001 alone, and upregulated the expressions of cell apoptosis-related protein p53. These findings first confirmed the effect of Rhein and RAD001 combination on GC apoptosis.

PI3K/Akt/mTOR pathway activation promotes the invasion and migration of GC cells [41,42]. p-PI3K could activate Akt to form p-Akt, and PI3K inhibitor LY294002 could repress the expressions of p-PI3K, p-Akt, and p-mTOR in GC cells, as well as induce the apoptosis and suppress the proliferation of GC cells [43]. mTOR pathway is modulated by PI3K/Akt pathway, and suppressing PI3K/Akt pathway can repress the expression of p-PI3K and p-Akt, thereby inhibiting p-mTOR expression in GC [44]. Importantly, p-mTOR can lead to worse prognosis and shorter overall survival rate in GC [45]. Researchers also have shown evidences that PI3K/Akt/mTOR pathway is a key pathway regulated by Rhein to exert its anticancer effect on GC [46,47]. Moreover, PI3K/Akt/mTOR pathway modulates RAD001 in epithelial mesenchymal transition phenotype, apoptosis, and cell cycle arrest of GC cells [48]. We further confirmed that PI3K/Akt/mTOR pathway activation can be inhibited by Rhein and RAD001 combination than the administration of Rhein or RAD001 alone. These results indicated that PI3K/Akt/mTOR pathway involves in RAD001 and Rhein exerted synergistic anticancer effects on GC cells.

RAD001 can inhibit tumor growth of GC cell xenografts [12]. However, whether RAD001 and Rhein combination can exert synergistic anticancer effects on GC in vivo is still not known. In this in vivo experiment, we found that the combination of Rhein and RAD001 significantly reduced tumor weight and volume, repressed PI3K/AKT/mTOR pathway activation, and decreased tumor cell proliferation marker Ki-67 expression than the administration of Rhein or RAD001 alone, which indicated RAD001 and Rhein combination exerted synergistic cancer prevention on GC in vivo xenograft model.

Limitations: Whether GC cell autophagy participates in the process of synergistic cancer prevention of
RAD001 and Rhein combination is not investigated. In addition, the effect of Rhein on RAD001-resistant GC cells is not explored. We will focus on the effect of RAD001 and Rhein combination on GC cell autophagy, and clarify if there are microRNAs or other signaling pathways involved in the regulation of RAD001 and Rhein combination in GC.

**Conclusion**

Our data calculate IC50 value for Rhein and RAD001 dose response, and finish-dose selection for Rhein and RAD001. In addition, our data suggest RAD001 and Rhein combination exerts their synergistic cancer prevention through suppressing GC cell proliferation and invasion, and promoting GC cell apoptosis in vitro, and in vivo experiments verified Rhein and RAD001 combination repressed tumor growth and PI3K/AKT/mTOR pathway activation.

**Disclosure statement**

No potential conflict of interest was reported by the author(s).

**Funding**

This study was supported by National Natural Science Foundation of China (No.81373988), Subject Innovation Team of Shaanxi University of Chinese Medicine (No.2019-QN02) and Project of Xianyang science and Technology Bureau (No. 2018K02-108).

**Author contributions**

FG&ZF designed the study, FG, RL,PW&LO performed the experiment, FG wrote the manuscript, ML&YB analyzed the data, WL&ZF edited the manuscript.

**References**

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.

[2] Ye T, Yang M, Huang D, et al. MicroRNA-7 as a potential therapeutic target for aberrant NF-κB-driven distant metastasis of gastric cancer. J Exp Clin Cancer Res. 2019;38(1):55.

[3] Liu C, Yang G, Liu N, et al. Effect of IncRNA BNC2-AS1 on the proliferation, migration and invasion of gastric cancer cells. Clin Lab. 2018;64(11). DOI:10.7754/ClinLab.2018.180537

[4] Zhang W, Wang Y, Zhu Z, et al. Propofol inhibits proliferation, migration and invasion of gastric cancer cells by up-regulating microRNA-195. Int J Biol Macromol. 2018;120(P A):975–984.

[5] Silva G, Teixeira Lima F, Seba V, et al. Curcumin analog CH-5 suppresses the proliferation, migration, and invasion of the human gastric cancer cell line HGC-27. Molecules. 2018;23(2):279.

[6] Katai H, Ishikawa T, Akazawa K, et al. Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese gastric cancer association (2001-2007). Gastric Cancer. 2018;21(1):144–154.

[7] Sharma M, Duan Z, Zhao H, et al. Real-world patterns of everolimus use in patients with metastatic breast cancer. Oncologist. 2020;25(11):937.

[8] Sheng X, Yan X, Chi Z, et al. Phase I trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma. EBioMedicine. 2020;55:102755.

[9] El Dika I, Mayer RJ, Venook AP, et al. A multicenter randomized three-arm phase II study of (1) everolimus, (2) estrogen deprivation therapy (EDT) with letrozole + letrozole, and (3) everolimus + EDT in patients with unresectable fibrolamellar carcinoma. Oncologist. 2020;25(11):925.

[10] Lang SA, Gaumann A, Koehl GE, et al. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer. 2007;120(8):1803–1810.

[11] Huang YK, Kang WM, Ma ZQ, et al. NUCKS1 promotes gastric cancer cell aggressiveness by upregulating IGF-1R and subsequently activating the PI3K/Akt/mTOR signaling pathway. Carcinogenesis. 2019;40(2):370–379.

[12] Celikda K, Preusser M, Woehrler A, et al. Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. Cancer Biol Ther. 2008;7(9):1377–1385.

[13] Taguchi F, Koida Y, Katanasaka Y, et al. Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination. Invest New Drugs. 2011;29(6):1198–1205.

[14] Cao Y, Qu J, Li C, et al. Celecoxib sensitizes gastric cancer to rapamycin via inhibition of the Cbl-b-regulated PI3K/Akt pathway. Tumour Biol. 2015;36(7):5607–5615.

[15] Liu H, Yao Y, Zhang J, et al. MEK inhibition overcomes everolimus resistance in gastric cancer. Cancer Chemother Pharmacol. 2020;85(6):1079–1087.

[16] Li X, Liu Y, Zhao Y, et al. Rhein derivative 4F inhibits the malignant phenotype of breast cancer by down-regulating Rac1 protein. Front Pharmacol. 2020;11:754.
[17] Ma Y-L, Chen F, Shi J. Rhein inhibits malignant phenotypes of human renal cell carcinoma by impacting on MAPK/NF-κB signaling pathways. Onco Targets Ther. 2018;11:1385–1394.

[18] Lee SJ, Lee J, Lee J, et al. Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. Invest New Drugs. 2013;31 (6):1580–1586.

[19] Yoon DH, Ryu MH, Park YS, et al. Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br J Cancer. 2012;106(10):1039–1044.

[20] Kang W, Zheng X, Wang P, et al. Deguelin exerts antitumor activity of human gastric cancer MGC-803 and MKN-45 cells in vitro. Int J Mol Med. 2018;41 (6):3157–3166.

[21] Xu T, Liu P, Li Q, et al. Inhibitory effects of everolimus in combination with paclitaxel on ADAM10-resistant breast cancer cell line MDA-MB-231. Taiwanese J Obstetrics Gynecol. 2020;59(6):828–834.

[22] Ni T, Wang H, Li D, et al. Huachansu Capsule inhibits the proliferation of human gastric cancer cells via Akt/mTOR pathway. Biomed Pharmacot. 2019;118:109241.

[23] Yan XY, Zhang JJ, Zhong XR, et al. The LINCC00365/SCGB2A1 (mammaglobin B) axis down-regulates NF-κB signaling and is associated with the progression of gastric cancer. Cancer Manag Res. 2020;12(6):621–631.

[24] Zhang W, Niu J, Ma Y, et al. The synergistic antitumor activity of chidamide in combination with bortezomib on gastric cancer. Onco Targets Ther. 2020;13:3823–3837.

[25] Yuan G, Ding W, Sun B, et al. Upregulated circRNA_102231 promotes gastric cancer progression and its clinical significance. Bioengineered. 2021;12 (1):4936–4945.

[26] Liu Z, Cai C, Du J, et al. TCMIO: a comprehensive database of traditional chinese medicine on immuno-oncology. Front Pharmacol. 2020;11:439.

[27] Liu J, Yan S, Hu J, et al. MiRNA-4537 functions as a tumor suppressor in gastric cancer and increases the radiosensitivity of gastric cancer cells. Bioengineered. 2021;12(1):8457–8467.

[28] Ge H, Tang H, Liang Y, et al. Rhein attenuates inflammation through inhibition of NF-κB and NALP3 inflammasome in vivo and in vitro. Drug Des Devel Ther. 2017;11:1663–1671.

[29] Lin ML, Chung JG, Lu YC, et al. Rhein inhibits invasion and migration of human nasopharyngeal carcinoma cells in vitro by down-regulation of matrix metalloproteinases-9 and vascular endothelial growth factor. Oral Oncol. 2009;45(5):531–537.

[30] Chen J, Luo B, Wen S, et al. Discovery of a novel rhein-SAHA hybrid as a multi-targeted anti-glioblastoma drug. Invest New Drugs. 2020;38 (3):755–764.

[31] Li Y, Xu Y, Lei B, et al. Rhein induces apoptosis of human gastric cancer SGC-7901 cells via an intrinsic mitochondrial pathway. Braz J Med Biol Res. 2012;45 (11):1052–1059.

[32] Lorenzen S, Stahl M, Hofheinz RD, et al. Influence of taxanes on treatment sequence in gastric cancer. Oncol Res Treat. 2020;43(1–2):42–47.

[33] Du C, Li D-Q, Li N, et al. DDX5 promotes gastric cancer cell proliferation in vitro and in vivo through mTOR signaling pathway. Sci Rep. 2017;7:42876.

[34] Yang L, Lin S, Kang Y, et al. Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3 pathway. J Exp Clin Cancer Res. 2019;38(1):31.

[35] Zhuang Y, Bai Y, Hu Y, et al. Rhein sensitizes human colorectal cancer cells to EGFR inhibitors by inhibiting STAT3 pathway. Onco Targets Ther. 2019;12:5281–5291.

[36] Han NN, Li X, Tao L, et al. Doxorubicin and rhein loaded nanomicelles attenuates multidrug resistance in human ovarian cancer. Biochem Biophys Res Commun. 2018;498(1):178–185.

[37] Shen Z, Zhu B, Li J, et al. Rhein augments antiproliferative effects of atezolizumab based on breast cancer (4T1) regression. Planta Med. 2019;85(14–15):1143–1149.

[38] D-z X, Q-r G, Tian Y, et al. Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer. BMC Cancer. 2010;10:536.

[39] Wang A, Jiang H, Liu Y, et al. Rhein induces liver cancer cells apoptosis via activating ROS-dependent JNK/c-Jun/caspase-3 signaling pathway. J Cancer. 2020;11(2):500–507.

[40] Shi P, Huang Z, Chen G. Rhein induces apoptosis and cell cycle arrest in human hepatocellular carcinoma BEL-7402 cells. Am J Chin Med. 2008;36(4):805–813.

[41] Jiang C, Ma Z, Zhang G, et al. CSN2K2A1 promotes gastric cancer invasion through the PI3K-Akt/mTOR signaling pathway. Cancer Manag Res. 2019;12(1):10135–10143.

[42] Lee HJ, Venkatarame Gowda Saralamma V, Sm K, et al. Pectolinarigenin induced cell cycle arrest, autophagy, and apoptosis in gastric cancer cell via PI3K/AKT/mTOR signaling pathway. Nutrients. 2018;10 (8):1043.

[43] Cai C, Dang W, Liu S, et al. Anthrax toxin receptor 1 tumor endothelial marker 8 promotes gastric cancer progression through activation of the PI3K/AKT/mTOR signaling pathway. Cancer Sci. 2020;111 (4):1132–1145.

[44] Chen H, Guan R, Lei Y, et al. Lymphangiogenesis in gastric cancer regulated through Akt/mTOR-VEGF-C/VEGF-D axis. BMC Cancer. 2015;15:103.

[45] Cao G-D, Chen K, Chen B, et al. Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients. BMC Cancer. 2017;17(1):841.

[46] Wu C, Cao H, Zhou H, et al. Research progress on the antitumor effects of rhein: literature review. Anticancer Agents Med Chem. 2017;17(12):1624–1632.
[47] Bu T, Wang C, Jin H, et al. Organic anion transporters and PI3K–AKT–mTOR pathway mediate the synergistic anticancer effect of pemetrexed and rhein. J Cell Physiol. 2020;235(4):3309–3319.

[48] Chen D, Lin X, Zhang C, et al. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway. Cell Death Dis. 2018;9(2):123.